复宏汉霖(02696) - 2025 H1 - 电话会议演示

Henlius (2696.HK) 2025 Interim Results Investor Presentation August 2025 © 2025 Henlius. 2025 1H Business Highlights & 01 Company Strategy © 2025 Henlius. Revenue Tops 2.8B RMB with Net Profit of 386M RMB >1B RMB BD • The BD contract cash inflow of RMB >1B in 2025 H1, a 280% YoY growth • HLX13 (Ipilimumab) out-licensed to Sandoz with upfront payment of USD 31 million and a total amount up to USD 300 million • HLX15 (daratumumab) out-licensed to Dr. Reddy's with upfront payment of USD 33 million and a total ...